PML: An emerging tumor suppressor and a target with therapeutic potential

Eric L. Reineke, Huang Ying Kao

研究成果: Review article同行評審

18 引文 斯高帕斯(Scopus)

摘要

Though originally discovered as a tumor suppressor in Acute Promyelocytic Leukemia (APL), the importance of promyelocytic leukemia protein (PML) in cancers of other origins has not been widely studied. Recent studies have shown that multiple types of cancers show decreased expression of PML protein, though the mechanisms leading to this down-regulation are unknown. Decreased expression of PML can result in loss of cell cycle control and prevention of apoptosis and is likely a key event in the promotion of oncogenesis. Many of these effects are due to changes in the transcriptional profile of the cell as a result of decreased size and number of PML nuclear bodies. Several mouse studies confirm the contribution of PML to oncogenesis and cancer progression. It is important to not only further define a role for PML as a tumor suppressor, but also to begin to develop strategies to target PML therapeutically.

原文English
頁(從 - 到)219-226
頁數8
期刊Cancer Therapy
7
發行號ISSUE A
出版狀態Published - 2009

All Science Journal Classification (ASJC) codes

  • 腫瘤科
  • 藥理
  • 癌症研究

指紋

深入研究「PML: An emerging tumor suppressor and a target with therapeutic potential」主題。共同形成了獨特的指紋。

引用此